__NUXT_JSONP__("/drugs/Ropeginterferon_Alfa-2B", (function(a,b,c,d,e,f){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:b,conditionIndication:"Besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.",inn:b,marketingAuthorisationDate:"2019-02-15 01:00:00",marketingAuthorisationHolder:"AOP Orphan Pharmaceuticals GmbH",medicineName:c,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fbesremi"}],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1335098-50-4",chebiId:d,chemicalFormula:d,definition:"A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b), in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon administration of ropeginterferon alfa-2b, IFN-a2b targets and binds to specific IFN cell-surface receptors. This activates IFN-mediated signal transduction pathways and induces the transcription and translation of genes with IFN-specific response elements (ISREs). Their protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a single positional isomer which further increases its stability and half-life.",fdaUniiCode:"981TME683S",identifier:"C111892",preferredName:e,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C1845"],synonyms:["AOP2014",c,"P-1101","P1101","PEG-P-IFN-Alfa-2b","PEG-P-IFN-Alpha-2b","PEG-Proline-Interferon Alfa-2b","ROPEGINTERFERON ALFA-2B",e]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FRopeginterferon_Alfa-2B",extension:".json",createdAt:f,updatedAt:f}}],fetch:{},mutations:void 0}}("Ropeginterferon_Alfa-2B","ropeginterferon alfa-2b","Besremi","","Ropeginterferon Alfa-2B","2021-10-30T13:18:22.013Z")));